跳至主要内容
临床试验/NCT02020122
NCT02020122已完成不适用

Pain Prevention and Treatment Through the Enhancement of the Anti-nociceptive Component of Pain Modulation Profiles

Rambam Health Care Campus1 个研究点 分布在 1 个国家目标入组 5 人开始时间: 2014年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
5
试验地点
1
主要终点
The changes in pain response after administration of duloxetine and pregabalin

研究概览

简要总结

To utilize the plasticity of the central pain pathways in order to (i) shift individuals with a pro-nociceptive pain modulation profile towards an anti-nociceptive one, and (ii) assess its relevance in minimizing pain-derived morbidity.

详细描述

In the project proposed here our main aim is to shift pain modulation towards anti-nociception as a novel approach to pain prevention and treatment. Our first hypothesis is that individual's modulation profile, when not anti-nociceptive, can be pharmacologically shifted into being anti-nociceptive. We assert (the first hypothesis) that such shift can be optimized by coupling the drug's mode of action with the individual's pain modulation profile; based on limited available data, it is suggested that less efficient inhibitory pain modulation will be modified best by serotonin-norepinephrine reuptake inhibitors (SNRIs), whereas enhanced facilitatory modulation will be modified best by Ca++ channel ligands. Pain modulation will be assessed by psychophysical tools, and will include dynamic tests of pain modulation. The conditioned pain modulation (CPM) test protocol will be used for assessing pain inhibition, and the temporal summation (TS) test protocol will be used for assessment of pain facilitation. Our second hypothesis is that SNRIs will be most efficacious in shifting individuals into being antinociceptive if these individuals had lower activation of the anterior brain pain network in the CPM test paradigm. In turn, Ca++ channel ligands will be most efficacious for individuals showing enhanced activation of the posterior pain network sites in response to the TS test protocol. Our third hypothesis is that an anti-nociceptive pain modulation profile protects individuals from acquiring pain. The model we chose for this study is surgery for coronary artery bypass grafting (CABG). Individuals scheduled for surgery, who are pain free, will be assigned to 3 arms - (1) duloxetine (DUL) (SNRI), (2) pregabalin (PGB) (Ca++ channel ligand) and (3) placebo. Drugs will be taken for 48 hours prior to surgery in a double-blind non cross-over parallel design. Pain modulation will be assessed before treatment, 2-4 hours prior to surgery and at its end, 6 weeks before surgery. Post operative acute and chronic pain will be assessed up to 2 month after surgery.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Otherwise healthy, age 18-75.

排除标准

  • Regular use of analgesia for any purpose, including SNRIs, gabapentins, COX inhibitors.
  • Presence of diagnosed chronic pain disorders, psychiatric disorders, cognitive and /or neurological deficit.
  • Inability to give informed consent, communicate and understand the purpose and instructions of this study.
  • Pregnant or nursing women.

研究组 & 干预措施

Duloxetine

Active Comparator

DUL 60mg x once a day x 2 days. This arm will also take 2 non-active placebo x once a day x 2 days

干预措施: Duloxetine (Drug)

Duloxetine

Active Comparator

DUL 60mg x once a day x 2 days. This arm will also take 2 non-active placebo x once a day x 2 days

干预措施: Placebo (Drug)

Pregabalin

Active Comparator

PGB 150mg x twice a day x 2 days

干预措施: Pregabalin (Drug)

Placebo

Placebo Comparator

Non active placebo x twice a day x 2 days

干预措施: Placebo (Drug)

结局指标

主要结局

The changes in pain response after administration of duloxetine and pregabalin

时间窗: 3 years

The changes in the excitatory and inhibitory pain modulation responses (assessed by temporal summation and conditioned pain modulation) will be examined before and after the administration of duloxetine and pregabalin in the set of pre and post coronary artery bypass grafting surgery.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

d_yarnitsky

Professor, Head of Neurology Deapartment

Rambam Health Care Campus

研究点 (1)

Loading locations...

相似试验